Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7274569 | 0.83 | KDM4E (0.56) | RAB9AALDH1A1KDM4ENPC1GLA | |
| SCHEMBL18065871 | 0.81 | RAB9A (0.61) | RAB9AALDH1A1KDM4ENPC1GLA | |
| SCHEMBL5327076 | 0.81 | KDM4E (0.55) | RAB9AALDH1A1KDM4ENPC1GLA | |
| SCHEMBL22527890 | 0.81 | KDM4E (0.52) | RAB9AALDH1A1KDM4ENPC1GLA | |
| SCHEMBL2126735 | 0.80 | NPC1 (0.72) | RAB9AALDH1A1KDM4ENPC1GLA | |
| SCHEMBL28360462 | 0.80 | ALDH1A1 (0.50) | RAB9AALDH1A1KDM4ENPC1GLA | |
| Bromide SCHEMBL1691882 | 0.79 | NPC1 (0.70) | RAB9AALDH1A1KDM4ENPC1GLA | |
| SCHEMBL408219 | 0.79 | RAB9A (0.56) | RAB9AALDH1A1KDM4ENPC1GLA | |
| SCHEMBL16194638 | 0.78 | KDM4E (0.52) | RAB9AALDH1A1KDM4ENPC1GLA | |
| SCHEMBL31309555 | 0.78 | ALDH1A1 (0.52) | RAB9AALDH1A1KDM4ENPC1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2026-01-08 | — | — | US | disclosed |
| WO-2025076501-A1 | HIGH THROUGHPUT PARALLEL SYNTHESIS OF SMALL MOLECULE DEGRADERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119585252-A | Bicyclic heteroaryl containing compounds as IKZF2 degrading agents | 翁科皮亚治疗公司和SK生命科学实验室 | 2025-03-07 | — | — | CN | disclosed |
| WO-2025006293-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | MERCK SHARP & DOHME LLC (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240252655-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | NOVARTIS AG (CH) | 2024-08-01 | — | — | US | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097355-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | VICINITAS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4329815-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | Novartis AG (CH) | 2024-03-06 | — | — | EP | disclosed |
| US-20210347771-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-11-11 | — | — | US | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| US-20190144439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-05-16 | — | — | US | disclosed |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-25 | — | — | US | disclosed |
| EP-3365340-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017070089-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-04-27 | — | — | WO | disclosed |
| US-20170107216-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-04-20 | — | — | US | disclosed |
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | RAB9A 1946/4885ALDH1A1 104/4885KDM4E 1276/4885 |
| US-20240252655-A1 | DEUBIQUITINASE-TARGETING CHIMERAS AND RELATED METHODS | USP2, USP1, USP28 | RAB9A 996/4885ALDH1A1 3713/4885KDM4E 2275/4885 |
| US-20260007680-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | RAB9A 1082/4885ALDH1A1 1444/4885KDM4E 2486/4885 |
| US-20100092385-A1 | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | APP, PSEN1, PSEN2 | RAB9A 1145/4885ALDH1A1 1631/4885KDM4E 3283/4885 |
| US-20190144439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | RAB9A 2431/4885ALDH1A1 247/4885KDM4E 3674/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | RAB9A 2152/4885ALDH1A1 409/4885KDM4E 1970/4885 |
| US-20170107216-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | RAB9A 2431/4885ALDH1A1 247/4885KDM4E 3674/4885 |
| US-20210347771-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | RAB9A 2431/4885ALDH1A1 247/4885KDM4E 3674/4885 |
| US-20180305315-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | RAB9A 1946/4885ALDH1A1 104/4885KDM4E 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.